Furney Natalie Anne Marie 4

What Happened

• Natalie Anne Marie Furney, Global General Counsel of Takeda Pharmaceutical Co. Ltd. (TAK), received an award of 43,886 restricted stock units (RSUs) on 2026-07-01. The reported acquisition price is $0.00 (compensation grant), total reported value $0 at grant date.
• Footnote: each RSU is a contingent right to receive one American Depositary Share (ADS). The RSUs vest in three equal annual installments beginning July 1, 2027. This is a compensation grant (award), not an open-market purchase or sale.

Key Details

• Transaction date: 2026-07-01 (Grant/Award; Form 4 filed 2026-07-06).
• Shares/units granted: 43,886 RSUs; acquisition price reported as $0.00.
• Shares owned after transaction: Not disclosed in the provided filing.
• Footnote: RSUs convert to one ADS each upon vesting; vesting in three equal annual installments starting 7/1/2027.
• Filing timeliness: Form filed on 2026-07-06 (five days after the grant). That is later than the common two-business-day Section 16 filing window and may represent a late filing — check the SEC filing for any late-filing notation.

Context

• RSUs are a deferred-compensation award: they represent a right to receive shares in the future if vesting conditions are met, and no cash was paid at grant. Such awards are common executive compensation and do not indicate an open-market purchase or immediate change in cash exposure.
• For retail investors, grants increase potential future dilution but do not necessarily signal the insider's personal market view.